➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Mallinckrodt
Johnson and Johnson
Medtronic
Merck

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OXYTOCIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Oxytocin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University N/A 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) N/A 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗ Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-Scheduled Cesarean Section Completed Basel Women’s University Hospital Phase 2 1999-01-01 Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00114439 ↗ Lithium Cannabis Withdrawal Study Completed The University of New South Wales Phase 2 2005-09-01 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00114439 ↗ Lithium Cannabis Withdrawal Study Completed Sydney South West Area Health Service Phase 2 2005-09-01 This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.
NCT00116350 ↗ Misoprostol for the Treatment of Postpartum Hemorrhage Completed Family Care International N/A 2005-07-01 The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxytocin

Condition Name

Condition Name for Oxytocin
Intervention Trials
Postpartum Hemorrhage 73
Healthy 45
Schizophrenia 28
Oxytocin 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxytocin
Intervention Trials
Hemorrhage 129
Postpartum Hemorrhage 122
Disease 31
Schizophrenia 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxytocin

Trials by Country

Trials by Country for Oxytocin
Location Trials
United States 302
Egypt 58
Canada 57
China 37
France 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxytocin
Location Trials
California 58
North Carolina 29
New York 28
Massachusetts 23
Maryland 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxytocin

Clinical Trial Phase

Clinical Trial Phase for Oxytocin
Clinical Trial Phase Trials
Phase 4 106
Phase 3 65
Phase 2/Phase 3 14
[disabled in preview] 207
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxytocin
Clinical Trial Phase Trials
Completed 233
Recruiting 167
Not yet recruiting 157
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxytocin

Sponsor Name

Sponsor Name for Oxytocin
Sponsor Trials
University of Electronic Science and Technology of China 32
Samuel Lunenfeld Research Institute, Mount Sinai Hospital 27
Cairo University 19
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxytocin
Sponsor Trials
Other 808
Industry 38
NIH 32
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Colorcon
Medtronic
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.